Masashi Wakabayashi

3PUBLICATIONS
48CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

|Oct 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).

Keiju Aokage, Shohei Koyama, Shogo Kumagai

Pageof 1

Frequent Collaborators

2 joint publications

Kenichi Harano

2 joint publications

Toru Mukohara

2 joint publications

Suguru Odajima

2 joint publications

Hideki Furuya